Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 14/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 13/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 13/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 10/20 | 1.00 |
| ▸ | PRKCA | P17252 | 8/20 | 0.74 |
| ▸ | PRKCB | P05771 | 4/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.74 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.74 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.74 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | LATS1 | O95835 | 3/20 | 0.51 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326372 | 0.86 | PRKCH (0.75) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL3327608 | 0.85 | PRKCH (1.00) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL3325947 | 0.84 | PRKCD (0.73) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL3325495 | 0.83 | PRKCD (1.00) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL3325548 | 0.82 | PRKCD (0.76) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL17197936 | 0.79 | PRKCD (0.67) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL13337102 | 0.79 | PRKCD (1.00) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL13336981 | 0.79 | PRKCH (1.00) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL18391620 | 0.79 | PRKCD (1.00) | PRKCHPRKCDPRKCEPRKCQPRKCA | |
| SCHEMBL3325753 | 0.78 | PRKCD (0.69) | PRKCHPRKCDPRKCEPRKCQPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | PRKCH 22/4885PRKCD 63/4885PRKCE 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.